NEWS
Oct 02, 2026

Healthgevity Introduces hydraCELL+™, Featuring Formulation IP Developed by the Seeds Foundation for Cellular Research

BREAKING NEWS

INTERLAKEN, N.J., [October 2, 2026] — Healthgevity, a practitioner-focused precision longevity nutrition company, announced the launch of hydraCELL+™, a cellular hydration and muscle-support formula built on proprietary formulation IP developed through the Seeds Foundation for Cellular Research and licensed to Healthgevity.

The formula reflects the cellular medicine approach advanced by William Seeds, MD, and the Seeds Scientific Research & Performance Institute, bringing that foundation into a practical nutritional option for practitioners working in healthspan, weight management and performance care.

Muscle plays a central role in healthy aging, supporting mobility, metabolic health and physical resilience. Maintaining muscle strength and function is an important consideration during aging, caloric restriction and demanding training. hydraCELL+™ was developed to support muscle physiology through complementary approaches to cellular hydration, nutrient signaling and energy availability.*

Each serving combines 8 g of Pürest Creatine™ (creatine monohydrate), 10 g of trehalose, 5 g of L-alanine, 4 g of glycine, 3 g of L-glutamine and 3 g of L-leucine. The formula is organized around three complementary actions:

  • Volumize: Creatine supports intracellular hydration and healthy muscle cell volume.*
  • Signal: Leucine supports nutrient signaling involved in muscle protein synthesis.*
  • Perform: Creatine supports phosphocreatine availability and ATP regeneration for exercise performance.*

“Maintaining muscle is a priority across weight management, healthy aging and performance care,” said Michael Antonelli, Founder and CEO of Healthgevity. “hydraCELL+ brings the cellular medicine approach advanced by Dr. Seeds into a practical, research-informed formula that combines creatine and targeted amino acids to support cellular hydration, muscle signaling and performance.”

hydraCELL+™ is designed to complement adequate dietary protein, resistance exercise and individualized practitioner-directed care. Its ingredient foundation includes creatine monohydrate, an extensively studied nutritional ingredient for muscle strength and exercise performance. Ingredient research informs the formulation; it does not establish clinical outcomes for the finished product.

hydraCELL+™ is available now through Healthgevity practitioner wholesale accounts, with direct-to-patient ordering and fulfillment available through the Healthgevity HCP affiliate program.

For product details and directions, visit healthgev.com/products/hydracell.

Healthgevity is a Trusted Partner of SSRP, reflecting a shared commitment to supporting practitioners with science-informed tools, education and resources aligned with the evolving field of cellular medicine. Through the Trusted Partner Network, SSRP works with organizations that demonstrate a commitment to quality, scientific integrity and meaningful support of the SSRP provider community.

For more information and to view the Healthgevity Partner Page, visit:
SSRP Healthgevity Partner Page

About Healthgevity 

Healthgevity® develops practitioner-exclusive formulations built on Precision Signaling Nutrition™, combining bioactive peptides, biofunctional proteins and clinically informed nutraceuticals. Working alongside physicians, researchers and biotechnology innovators, Healthgevity develops nutritional tools for healthy aging, metabolic health, gut health and performance.


*These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.

RELATED RESOURCES

Continue exploring related topics.

VIEW ALL
Uncategorized Oct 22, 2026
SSRP Institute Welcomes PharmaNutra as New Trusted Partner
PARTNER ANNOUNCEMENT WILLOUGHBY, Ohio, [October 22, 2026] — The SSRP Institute announces that PharmaNutra has joined its Trusted Partner Network following nomination and completion of the SSRP’s internal review process. Founded in Italy in 2003, PharmaNutra is a pharmaceutical and nutraceutical company focused on the research, development, and production of nutritional supplements and medical devices. […]
READ NEWS
VIDEO
Cellular Medicine Mondays
Oct 19, 2026
Ep. 110 - Phenotyping is Essential to Cellular Medicine
Preview only
Rabbit Holes – Episode 110

The Macrophage Mystery: Decoding Aging

In Part 3 of our Anti-Aging Mini Mastermind, Dr. Seeds explores how aging alters PGE2/EP2 signaling, influencing macrophage metabolism, immune function, and inflammation, and examines potential therapeutic implications.
Articles referenced: (2026 Article) (2021 Article)

Preview Only — Become a member for full access
VIDEO
Cellular Medicine Mondays
Oct 12, 2026
Ep. 109 - Anti-Aging Mini Mastermind Part 2
Preview only
Journal Club – Episode 109

Anti-Aging Mini Mastermind Part 2

In Part 2 of our Anti-Aging Mini Mastermind series, Dr. Seeds explores how PGE2 signaling and cellular metabolism influence inflammation, cognitive function, and aging, connecting foundational research to emerging discoveries in immunometabolism.  (2026 Article) (2021 Article)

Preview Only — Become a member for full access
ARTICLE
William Seeds, MD
Oct 8, 2026
EP2, Tissue-Resident Macrophages, and a New Mechanism of Organ Aging
William Seeds, MD Oct 8, 2026
EP2, Tissue-Resident Macrophages, and a New Mechanism of Organ Aging
Revisiting a Journal Club Article, “Restored clearance of senescent neutrophils by tissue-resident macrophages limits organ aging.” Science. 2026  Why This Paper Matters Most of the senescence conversation over the past decade has centered on a familiar cast: senescent fibroblasts, endothelial cells, adipocytes, and the drugs designed to clear them. This paper, which I discuss in […]
READ ARTICLE
VIDEO
Cellular Medicine Mondays
Oct 5, 2026
Ep. 108 - Dr. Seeds’ Office Hours
Preview only
Dr. Seeds’ Office Hours – Episode 108

Dr. Seeds’ Office Hours – Episode 108

Questions Answered:
1. ARA-290 for Post Op 47yo Male [0:53]
2. Cold Therapy and the Wim Hof Method [17:06]

Preview Only — Become a member for full access
VIDEO
Cellular Medicine Mondays
Sep 28, 2026
Ep. 107 - Anti-Ageing Mini Mastermind Part 1
Preview only
Journal Club – Episode 107

Mini Anti-Aging Mastermind Part 1: Restored clearance of senescent neutrophils by tissue-resident macrophages limits organ aging

Part 1 of a special Mini Anti-Aging Mastermind inspired by the recent Science article exploring how impaired clearance of senescent neutrophils may contribute to age-related organ decline. Dr. Seeds begins breaking down the cellular mechanisms behind the research and what they reveal about the biology of aging. (Article Link)

Preview Only — Become a member for full access
ARTICLE
William Seeds, MD
Sep 23, 2026
The Future of Regenerative Medicine May Begin with a Hair Follicle
William Seeds, MD Sep 23, 2026
The Future of Regenerative Medicine May Begin with a Hair Follicle
Why a Plucked Hair Follicle May Matter to the Future of Regenerative Medicine In this article, I return to a study that I discussed in a July Journal Club post. The study, published in Cells in 2024, investigated whether cells obtained from plucked, cryopreserved human hair follicles could be reprogrammed into induced pluripotent stem cells […]
READ ARTICLE
Peptide Therapy Certification 2026
The SSRP Peptide Therapy Certification course gives clinicians, researchers, and other healthcare providers a working method for applying Cellular Medicine principles to patient care through clinical peptide therapy. Across 19 faculty-led lessons, Dr. William Seeds and SSRP faculty, including Siobhan...
19 Lessons
15 hrs 43 min
View Course
VIDEO
Cellular Medicine Mondays
Sep 21, 2026
Ep. 106 - Peptide Support After Transplant: What to Consider First
Preview only
Dissecting Protocols – Episode 106

Peptide Support After Transplant: What to Consider First

Dr. Seeds explores how to protect graft integrity and identify the right cellular targets before considering peptide support in a patient six years post liver transplant.

Preview Only — Become a member for full access
SSRP Institute Sep 14, 2026
In Case You Missed it: FDA Approves Mounjaro (tirzepatide) for CVD
HEADLINE SCIENCE [Sept 14, 2026] – On August 28, 2026, the FDA expanded the indication for Mounjaro (tirzepatide), approving the dual GIP/GLP-1 receptor agonist to reduce the risk of major adverse cardiovascular events—including cardiovascular death, nonfatal myocardial infarction, and nonfatal stroke—in adults with type 2 diabetes at high cardiovascular risk. The decision makes tirzepatide the […]
READ NEWS

Subscribe to the SSRP Community Digest

Get the latest research and developments in the field of Cellular Medicine straight to your inbox every month.

This field is for validation purposes and should be left unchanged.